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A state-level study of opioid use disorder
treatment access and neonatal abstinence
syndrome
Elizabeth R. Wolf1,2* , Sebastian T. Tong3, Roy T. Sabo3,4, Steven H. Woolf3,5, Kassie Abbinanti3, James Pecsok3 and
Alex H. Krist3
Abstract
Background: Adult opioid use and neonatal abstinence syndrome (NAS) are growing public health problems in
the United States (U.S.). Our objective was to determine how opioid use disorder treatment access impacts the
relationship between adult opioid use and NAS.
Methods: We conducted a cross-sectional state-level ecologic study using 36 states with available Healthcare Cost
and Utilization Project State Inpatient Databases in 2014. Opioid use disorder treatment access was determined by
the: 1) proportion of people needing but not receiving substance use treatment, 2) density of buprenorphine-
waivered physicians, and 3) proportion of individuals in outpatient treatment programs (OTPs). The incidence of
NAS was defined as ICD-9 code 779.5 (drug withdrawal syndrome in newborn) from any discharge diagnosis field
per 1000 live births in that state.
Results: Unmet need for substance use disorder treatment correlated with NAS (r = 0.54, 95% CI: 0.26–0.73). The
correlation between adult illicit drug use/dependence and NAS was higher in states with a lower density of
buprenorphine-waivered physicians and individuals in OTPs.
Conclusions: Measures of opioid use disorder treatment access dampened the correlation between illicit drug
use/dependence and NAS. Future studies using community- or individual-level data may be better poised to
answer the question of whether or not opioid use disorder treatment access improves NAS relative to adult opioid use.
Keywords: Neonatal, Abstinence, Opioid, Substance, Withdrawal
Background
Neonatal abstinence syndrome (NAS) is a drug with-
drawal syndrome experienced by newborns whose
mothers have taken opioids or other substances during
pregnancy. Opioids that can cause NAS include illicit
substances (e.g., heroin) as well as legally prescribed
medications (e.g., oxycodone, methadone and buprenor-
phine). It is estimated that 60–80% of infants exposed to
opioids develop NAS [1]. Clinical manifestations of acute
NAS include irritability, hypertonicity, jitteriness, diar-
rhea, and failure to thrive [2]. Moderate to severe NAS
(27–91% of cases) requires treatment with opioids such
as morphine and methadone [2]. The need for additional
monitoring and treatment of NAS results in prolonged
hospital stays and high medical costs [2].
Concurrent with the surge in adult opioid use across
the United States [3], the incidence of NAS has also in-
creased dramatically—from 1.5 per 1000 hospital births
in 1999 to 14.4 per 1000 in 2014 [4]. The incidence of
NAS varies more than 30-fold between states; ranging
from 0.7 cases per 1000 live births in Hawaii to 33.4 per
1000 in West Virginia [5]. There are two primary long-
acting oral opioids that are used for adult opioid use
disorder treatment: methadone and buprenorphine.
Methadone is typically given in observed clinical settings,
whereas buprenorphine is typically taken by patients in
their own homes. There is growing use of buprenorphine
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in pregnant women as infants born to women taking
buprenorphine have better outcomes (e.g.: length of stay,
birth weight) compared with infants born to women tak-
ing methadone [6]. Since the medicines that are used for
treating opioid use disorder in pregnant women (e.g.
methadone and buprenorphine) can also result in NAS,
[7, 8] the relationship between opioid use disorder treat-
ment access and NAS is not yet well understood. Further-
more, it has been difficult to compare rates of NAS
between infants of mothers using illicit drugs such as her-
oin and those using prescribed medications for opioid use
disorder such as methadone and buprenorphine. Random-
ized controlled trials on this topic are considered unethical
and it is challenging to control for factors that might influ-
ence a pregnant woman’s enrollment in an opioid use
disorder treatment program within observational studies.
In addition to opioid replacement therapy, opioid use
disorder treatment programs may also include prenatal
care, case management, behavioral and mental health in-
terventions and social service support. We hypothesized
that there may be non-pharmacologic ways in which
opioid use disorder treatment programs might lower
rates of NAS such as improved mother-infant bonding,
increased breastfeeding, and decreased use of non-opioid
drugs [9]. This state-level analysis examined whether
NAS was associated with 1) the proportion of individuals
needing but not receiving substance use disorder treat-
ment (unmet need), 2) the density of buprenorphine-
waivered physicians, and 3) the number of individuals in
outpatient treatment programs (OTPs) per 100,000 popu-
lation. We hypothesized that: 1) measures of adult opioid
use (illicit drug use/dependence and opioid prescribing)
would be positively correlated with NAS, and 2) better
opioid use disorder treatment access would dampen the
positive association between adult opioid use and NAS.
Methods
Study design
We conducted a cross-sectional state-level ecologic ana-
lysis of pediatric discharge data from the Healthcare Cost
and Utilization Project’s State Inpatient Databases (HCUP
SID) and state-level variables from other publicly-available
databases.
Data sources, exposures and covariates
The percentage of patients needing but not receiving
treatment was obtained from open publicly available
databases including the National Survey on Drug Use
and Health (NSDUH), which provides state-level data on
illicit drug dependence or abuse in the past year and in-
dividuals who needed but did not receive treatment for
substance use [10]. The extent of the unmet substance
use treatment need in the United States is measured by
calculating the number of people aged 12 or older who
were classified as having substance use disorder based
on the NSDUH, but who did not receive substance use
treatment at a specialty facility in the past year [11].
State data on the number of individuals enrolled in
OTPs were obtained from the Substance Abuse and
Mental Health Services Administration [12]. State data
on the number of buprenorphine-waivered physicians
were gathered from the Drug Enforcement Administra-
tion (DEA) database [13]. The density (number per 100,
000 population) of buprenorphine-waivered physicians
was considered a proxy for opioid use disorder treat-
ment access since a DEA waiver is required to prescribe
buprenorphine, one of the two primary medications used
to treat opioid use disorder. While some buprenorphine-
waivered physicians may not provide care for pregnant
women, these measures reflect general access to opioid
use disorder services. We used the Intercontinental
Marketing Services Health National Prescription Audit
database to obtain physician prescribing rates for opioids
[14]. State-level data on demographic characteristics
(percentage of Hispanic or African American residents)
and the proportion of the population living in poverty or
in rural areas was gathered from the U.S. Census Bureau
[15]. All exposure and covariates were gathered from the
most recent year available.
Outcome
We identified cases of NAS by abstracting ICD-9 code
779.5 (drug withdrawal syndrome in newborn) [1] from
any discharge diagnosis field within the most recent
HCUP SID for pediatric hospitalizations [16]. Because
this time frame used ICD-9 rather than ICD-10 codes,
we were unable to distinguish between infants who
experienced withdrawal from illicit opioids and those
who experienced withdrawal from prescribed opioids.
We identified 35 states that had publicly available data
on NAS through the centralized HCUP SID from 2014.
The Virginia Department of Health also provided NAS
SID discharge data from 2014 [17] making a total of 36
states with available outcome data. The incidence of
NAS was reported as the number of NAS cases per 1000
live births in each state in 2014 [18].
Data analysis
Associations between continuous measurements and NAS
were measured using Pearson linear correlation coeffi-
cients, while NAS was compared between levels of binary
classifications using an equal variance two-sample t-test
and was compared between levels of polytomous classi-
fications using the Kruskal-Wallis test (due to small
group sizes). For any prevalence measures that had sig-
nificant associations with NAS, analysis of covariance
without interaction was used to reassess that associ-
ation for significance (and sign: positive or negative) in
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the presence of access and demographic measurements.
Due to small sample size, each access/demographic meas-
urement was included separately, and no interaction ef-
fects were modeled. The study’s relatively small sample
size (n = 36) prevented an analysis of opioid use disorder
treatment access measures as classical effect modifiers (i.e.
interaction terms). Instead, states were stratified as having
low or high density of buprenorphine-waivered physicians
and individuals in OTPs, based on whether they were
above or below the national median. The MEANS, CORR
and GLIMMIX procedures in the SAS Statistical Software
platform (version 9.4, Cary, NC, USA) were used for all
summaries and analyses. NAS frequencies were mapped
using EsriPress ArcGIS 10.2.
Results
Variability of access and NAS
Although the median density of buprenorphine-waivered
physicians was 8 (IQR: 5–14) per 100,000 population
(Table 1), the concentrations varied substantially across
the states, ranging from 2 per 100,000 in Iowa to 37 per
100,000 in Vermont (Fig. 1). Similarly, although the me-
dian OTP caseload was 80 (IQR: 46–114) individuals per
100,000 population, the values ranged from zero in
North Dakota to 278 per 100,000 in Maryland (Table 1).
The median incidence of NAS was 6 per 1000 live
births, ranging from 1 per 1000 live births in Hawaii to
36 per 1000 live births in Vermont. As shown in Table 2,
incidence rates of NAS correlated with state rates for
illicit drug dependence or abuse and opioid prescribing
(r = 0.36, 0.36, respectively; Table 2). NAS was more
common in more rural states and less common in states
with higher proportions of Hispanics (Table 2). NAS
was not significantly associated with the proportion of
African-Americans or those living in poverty (Table 2).
Treatment access and NAS
NAS correlated with levels of unmet need for substance
use disorder treatment (r = 0.54, 95% CI: 0.26–0.73). The
correlation between NAS and illicit drug use/depend-
ence was stronger in states with a lower density of
buprenorphine-waivered physicians and lower propor-
tion of individuals in OTPs (Table 3). In contrast, the
correlation between NAS and opioid prescribing was
stronger in states with higher-density of buprenorphine-
waivered physicians (Table 3).
Discussion
Patterns of neonatal abstinence syndrome
As expected, we found that higher state averages for
adult opioid prescribing and illicit drug use correlated
with higher rates of NAS. Adult opioid use and NAS
have both dramatically increased across the U.S. over
the past 10 years [3, 5]. The geographic and demo-
graphic trends of NAS that we observed are similar to
those observed with adult opioid use. For example, states
with the highest NAS incidence—Maine, Vermont, West
Virginia and Tennessee—are also known to have major
adult opioid crises [3]. Similarly, in our study, NAS was
more common in states with a higher proportion of
people living in rural domiciles. This is consistent with a
recent national study that found NAS to be more preva-
lent in rural counties [19]. We also found that NAS was
less common in states with greater proportions of His-
panics. This is consistent with data demonstrating that
the largest increases in prescription-overdose deaths and
heroin-overdose deaths are amongst whites [20]. Other
studies have found that white patients tend to have
greater access to opioid prescriptions in emergency
rooms [21] and that opioid prescriptions are more com-
mon in white pregnant women compared with pregnant
women of other races [7]. Interestingly, the state’s pro-
portion living in poverty did not seem to correlate with
NAS perhaps because of our limited sample size, the
lack of individual-level data or the interaction between
race and poverty at the state level.
Patterns of substance use disorder treatment access
Between states, there was wide variation in access to opi-
oid use disorder treatment. The states with the highest
levels of access tended to be in the Northeast and the
Pacific Northwest. New Mexico also had high levels of
Table 1 Summaries of opioid use, access, demographic and
outcome measurements
Opioid Use Median (IQR)
Illicit drug dependence or abuse per 1000 population 22 (20–25)
Opioid prescribing rates per 1000 population 774 (712–948)
Access
Number of buprenorphine -waivered physicians
per 100,000 population
8 (5–14)
Number of individuals in outpatient treatment
programs per 100,000 population
80 (46–114)
Unmet need (needing but not receiving treatment
for illicit drug use) per 1000 population
20 (18–21)
Demographics
Proportion of state population with incomes
below the federal poverty level
13% (11–16%)
Proportion of state population with rural
domicile
25% (11–34%)
Proportion of state population that is
Hispanic
10% (5–17%)
Proportion of state population that is African
American
6% (3–14%)
Outcome
Number of NAS cases per 1000 hospital
discharges under age 1
6 (4–10)
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opioid use disorder treatment access (Fig. 1). The Appa-
lachian states (Tennessee, Kentucky and West Virginia)
had some of the highest NAS incidence rates but had vari-
able levels of access to opioid use disorder treatment. Ken-
tucky had a low proportion of individuals in OTPs,
whereas West Virginia had a high proportion of
individuals in OTPs. All three had moderate levels of
buprenorphine-waivered physicians (Fig. 1).
Relationship between treatment access and neonatal
abstinence syndrome
Unmet need for substance use disorder treatment was posi-
tively and significantly correlated with NAS. This finding is
in concordance with a county-level study that found an asso-
ciation between shortage of mental health providers and
NAS [22]. However, the role of buprenorphine-waivered
physicians and OTPs on the relationship between adult
opioid use and NAS was less clear. There was a significant
correlation between illicit drug use/dependence and NAS in
states with lower levels of opioid use disorder treatment ac-
cess (both density of buprenorphine-waivered physicians and
individuals in OTPs). In states with higher levels of treatment
access, the correlation between NAS and illicit drug use/de-
pendence became non-significant. These findings were
largely driven by the wide variability in NAS in high-access
states (Fig. 2). Figure 2 shows that in particular, Maine, West
Virginia and Vermont had very high NAS rates relative to
rates of illicit drug use/dependence. One explanation for
these outliers is that there may be differences in the way
NAS is recognized or recorded in these states [23]. To ad-
dress this problem, some states are moving towards creating
NAS registries. However, these are not widespread enough
to study trends across states. Another explanation for these
outlying states is that there was increased use of non-opioid
drugs that increased NAS relative to illicit drug use.
In contrast to illicit drug use/dependence, the correlation
between NAS and opioid prescribing was actually stronger
in states with a greater density of buprenorphine-waivered
physicians. One explanation for this phenomenon is that
buprenorphine itself can result in NAS. There may also be
a diversion of prescribed buprenorphine to unintended re-
cipients. In addition, some states have graduate medical
education that includes buprenorphine-waivers for resi-
dents, but some of these physicians may not actually use
the waivers for opioid use disorder treatment.
Potential mechanisms
There are several potential mechanisms for how access
to opioid use disorder treatment might reduce the likeli-
hood of NAS. First, long-acting opioids used in opioid
use disorder treatment may pose a lower risk for NAS
than do short-acting drugs such as heroin or oxycodone
[24] due to steadier-state concentrations in the blood.
As mentioned previously, this hypothesis is difficult to
test in randomized controlled trials because it is consid-
ered unethical to not treat pregnant women with opioid
use disorders. Observational studies have shown that the
proportion of infants with NAS born to pregnant women
taking heroin (40–80%) overlap those treated with metha-
done (13–94%) and buprenorphine (22–67%) [2]. Second,
Fig. 1 Incidence of neonatal abstinence syndrome per 1000 live births, buprenorphine-waivered physicians per 100,000 population and
individuals in outpatient treatment programs per 100,000 population, by state. Figure was generated by authors
Table 2 Correlations between neonatal abstinence syndrome
and other predictive factors
Correlation (r; 95% CI) p-value
Adult opioid use
Proportion of individuals with illicit
drug dependence or abuse
0.36 (0.04–0.61) 0.03
Rate of opioid prescribing 0.36 (0.05–0.61) 0.02
Access
Number of buprenorphine-
waivered physicians per
100,000 population
0.71 (0.50–0.84) < 0.001
Number of individuals in
outpatient treatment programs
per 100,000 population
0.54 (0.26–0.73) < 0.001
Demographics
Proportion of state population
with incomes below the federal
poverty level
0.13 (−0.20–0.43) 0.44
Proportion of state population
with rural domicile
0.61 (0.35–0.77) < 0.001
Proportion of state population
that is Hispanic
− 0.38 (− 0.62 - -0.07) 0.02
Proportion of state population
that is African American
− 0.14 (− 0.44–0.19) 0.41
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women taking methadone or buprenorphine are often
permitted to breastfeed whereas women using heroin
women are not. Breastfeeding may reduce NAS
through opioid transfer in breastmilk and through
non-pharmacologic means through physical proximity
and comforting [25]. Third, opioid use disorder treat-
ment programs tend to have lower rates of non-opioid
drug use, which may further reduce the likelihood of
NAS [26, 27]. Fourth, opioid use disorder treatment
programs may include parenting, behavioral health or
mental health interventions that can improve mother-
infant bonding [28, 29]. Fifth, opioid use disorder
treatment may reduce NAS by non-pharmacologic
physiologic mechanisms, such as lowering maternal
cortisol levels [30].
Limitations
Our study has several limitations. The first limitation is
missing data: we lacked NAS data for 14 (28%) of the 50
states. Lacking a national database for NAS, we relied on
data from individual states, some of which do not par-
ticipate in centralized HCUP distribution. We do not
know if exclusion of these 14 states biased our results
and what direction that bias may have taken. Second,
the study relied on ICD-9 codes for diagnoses of NAS.
ICD-9 codes have been used widely by groups such as
the Centers for Disease Control and Prevention to
characterize NAS trends. Nevertheless, ICD-9 codes
have several limitations. ICD-9 codes can be generated
by non-medically trained personnel and may not always
accurately reflect patients’ medical conditions. Some
studies have found that ICD-9 codes tend to underesti-
mate cases of NAS [31, 32]. We would expect this type
of bias to be non-differential and not affect our
comparisons between states. Another problem with ICD-9
codes is that unlike the ICD-10 system (instituted in
2015), ICD-9 codes cannot distinguish between with-
drawal from illicit opioids and iatrogenic or prescribed
opioids. Furthermore, ICD-9 codes do not distinguish be-
tween withdrawal from opioids and non-opioid drugs. If
there were differences in non-opioid drug use between
states, these may have affected our results. When more re-
cent data becomes available, we may be able to study this
topic with more precision through use of ICD-10 codes
such as P96.1 (neonatal withdrawal symptoms from ma-
ternal use of drugs of opioid use disorder) and P96.2
(withdrawal symptoms from therapeutic use of drugs in
newborn). Furthermore, since the HCUP SID includes
discharge diagnoses from multiple hospitals, if an infant is
transferred from one hospital to another, that infant may
be counted more than once. This phenomenon may be
more likely to occur in rural locations.
Our small sample size and inability to control for
other state-level factors did not allow us to identify other
characteristics that could have moderated the effect of
adult opioid use on NAS. We did not have data on how
many pregnant women had opioid use disorder in various
states. The proportion of buprenorphine-waivered physi-
cians and individuals in OTPs are indirect measures of
treatment access. Certain clinics may have improved access
for pregnant women relative to men and non-pregnant
women. Other factors that could conceivably influence the
relationship between adult opioid use and NAS include 1)
the fertility rate amongst opioid-addicted mothers, 2)
the proportion of pregnant women using non-opioid
drugs such as tobacco, anti-depressants or benzodiaz-
epines (all of which have been shown to increase
rates of NAS) 3) the comprehensiveness or content of
Table 3 Correlations between neonatal abstinence syndrome and measures of adult opioid use stratified by density of
buprenorphine-waivered physicians and outpatient treatment program client case load
Correlation (r; 95% CI) p-value
Above median number of buprenorphine waivered physicians per 100,000 population (n = 20)1
Proportion of individuals with illicit drug dependence or abuse −0.04 (− 0.48–0.41) 0.86
Rate of opioid prescribing 0.48 (0.03–0.75) 0.03
Below median number of buprenorphine waivered physicians per 100,000 population (n = 18)1
Proportion of individuals with illicit drug dependence or abuse 0.73 (0.38–0.88) < 0.001
Rate of opioid prescribing 0.39 (−0.10–0.72) 0.12
Above median number of clients in outpatient treatment program per 100,000 population (n = 20)1
Proportion of individuals with illicit drug dependence or abuse 0.33 (−0.14–0.67) 0.16
Rate of opioid prescribing 0.27 (−0.21–0.63) 0.26
Below median number of clients in outpatient treatment program per 100,000 population (n = 18)1
Proportion of individuals with illicit drug dependence or abuse 0.59 (0.15–0.82) 0.01
Rate of opioid prescribing 0.38 (−0.11–0.72) 0.12
1“High” is above whereas “low” is below the national median; where the national median density of buprenorphine-waivered physicians = 8 per 100,000
population and the national median density of clients in outpatient treatment programs = 75 per 100,000 population
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opioid use disorder-treatment programs in each state,
4) the promotion of abstinence vs. opioid replacement
within opioid use disorder treatment programs, 5) the
ratio of public to private treatment programs 6) the
willingness of licensed providers to treat pregnant
women and 7) variability in the legal measures taken
against substance-abusing mothers [7, 33]. Some opi-
oid use disorder programs include behavioral inter-
ventions, mental health treatment and social service
support. These more comprehensive programs may be
more successful in reducing rates of NAS. Future
studies could examine the relationship between the
components of substance use disorder treatment pro-
grams and incidence of NAS. States can have differ-
ent interpretations of the Child Abuse Prevention and
Treatment Act (CAPTA), which requires notification
of child protective services for children affected by
drug withdrawal [34–36]. It is possible that in more
punitive states, pregnant women may be less likely to
seek opioid use disorder treatment even if it were
accessible to them.
In addition, our findings—which rely on state-level statis-
tics—are vulnerable to the “ecologic fallacy,” in which infer-
ences drawn from a population do not apply to individual
members. For example, just because a state has a certain
proportion of physicians who can prescribe buprenorphine,
does not mean that these physicians are equally distributed
throughout the population or accessible to those in need.
Furthermore, there is a wide variability in how many pa-
tients each buprenorphine-waivered physician treats [37].
Fig. 2 Cases of neonatal abstinence syndrome vs. illicit drug dependence and abuse, stratified by the density of buprenorphine-waivered
physicians and individuals in outpatient treatment programs. “High” and “Low” densities refer to a density of buprenorphine-waivered physicians
and individuals in outpatient treatment programs above and below the national median (8 physicians per 100,000 population and 80 individuals
per 100,000 population, respectively)
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Future studies using community- or individual-level data
may be better poised to answer the question of whether or
not opioid use disorder treatment access improves NAS
relative to adult opioid use. Lastly, our cross-sectional de-
sign did not allow for an analysis of temporal relationships.
We do not think this is a major concern with our study,
however, since we are studying exposures that affect adults,
specifically mothers, (who are by definition born before in-
fants) and an outcome that affects only infants.
Conclusions
In summary, unmet need for substance use disorder
treatment was positively correlated with NAS. The cor-
relation between adult illicit drug use/dependence and
NAS was dampened in states with higher levels of opioid
use disorder treatment access. Future studies utilizing
community or individual level data may be better able to
address whether adding opioid use disorder treatment
programs or buprenorphine-waivered physicians can re-
duce incidence of NAS. Since NAS results in substantial
infant morbidity and healthcare costs, the impact of
NAS should be taken into account when considering
public health measures that would improve access to
opioid use disorder treatment.
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